A European healthcare champion hiding value behind an overlooked valuation

In Europe, truly high-quality healthcare companies rarely come cheap. Structural growth, defensive demand, strong pricing power and high returns on capital usually translate into premium valuations. That is precisely why it stands out when a company manages to combine all of these attributes while trading at a meaningful discount to what its fundamentals would suggest. This is not a turnaround story or a cyclical rebound, but a case where market sentiment has quietly drifted away from underlying business quality.

The company in focus operates at the top end of a highly specialized medical-devices niche, with leading positions across Europe and a steadily expanding footprint in the United States. Returns on invested capital consistently exceed 20%, cash generation is resilient, and capital allocation remains disciplined. With shares priced roughly 40% below conservative fair-value estimates and a dividend that comfortably exceeds the sector average, the investment case is not just about…